BMS Signs New Agreement for Reyataz in sub-Saharan Africa and India

The agreement enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

Bristol-Myers Squibb Company has announced a new agreement with Matrix Laboratories Limited, a Mylan Company, to expand access to Reyataz (atazanavir sulfate).

The agreement enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

"The HIV treatment landscape has changed dramatically since 2001, when we first began our Global Access Program to help expand the availability of low-cost HIV medicines in the developing world,” said Frank Pasqualone, president, Intercontinental Region, Bristol-Myers Squibb. “Atazanavir is an important component of HIV combination therapy and this agreement facilitates broader availability of the medicine to help ensure patients can access appropriate treatm